Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital, Keelung, Chang Gung University, Taoyuan, Taiwan.
J Formos Med Assoc. 2011 Aug;110(8):511-7. doi: 10.1016/S0929-6646(11)60077-6.
BACKGROUND/PURPOSE: Patients with papillary thyroid microcarcinoma (PTMC) often have an excellent prognosis. We hypothesize that patients with multicentric PTMC are associated with good clinical outcome, although multicentricity in papillary thyroid carcinoma may be associated with poor prognosis.
Retrospective analysis of multicentric PTMC cases in one medical center enrolled from 1987 to 2008 was conducted. At the end of follow-up, patients were classified as "recurrence-free" or "recurrence or persistent disease". The tumor-node-metastasis (TNM) staging system was used, and (T1, N0, M0) was regarded as "early clinical stage", whereas (T3-4, any N, any M) or (any T, N1, or M1) was regarded as "advanced clinical stage".
There were 61 patients with a median age of 45 years. After a median follow-up period of 7.3 years (range: 2.1-22.1 years), the overall cause-specific survival rate was 98.36%. The patients with tumor diameters < 0.5 cm were all recurrence-free. Advanced clinical stage, especially distant metastasis, was highly associated with recurrence or persistent disease.
Our results demonstrate excellent prognosis in multicentric PTMC patients. No patients with tumor diameter < 0.5 cm had recurrence or persistent disease. Tumor size is an important risk factor in patients with multicentric PTMC.
背景/目的:患有甲状腺微小乳头状癌(PTMC)的患者通常预后良好。我们假设多中心 PTMC 患者的临床结局良好,尽管甲状腺乳头状癌的多中心性可能与预后不良相关。
对 1987 年至 2008 年期间在一家医疗中心确诊的多中心 PTMC 病例进行回顾性分析。随访结束时,患者被分为“无复发”或“复发或持续存在疾病”。采用肿瘤-淋巴结-转移(TNM)分期系统,(T1、N0、M0)被视为“早期临床分期”,而(T3-4、任何 N、任何 M)或(任何 T、N1 或 M1)被视为“晚期临床分期”。
共有 61 例患者,中位年龄为 45 岁。中位随访时间为 7.3 年(范围:2.1-22.1 年)后,总特异性生存率为 98.36%。肿瘤直径<0.5cm 的患者均无复发。晚期临床分期,特别是远处转移,与复发或持续存在疾病高度相关。
我们的结果表明多中心 PTMC 患者的预后良好。肿瘤直径<0.5cm 的患者均无复发或持续存在疾病。肿瘤大小是多中心 PTMC 患者的一个重要危险因素。